To hear about similar clinical trials, please enter your email below
Trial Title:
Transabdominal Gastric Contrast Ultrasound
NCT ID:
NCT05596864
Condition:
Transabdominal Gastric Contrast Ultrasound
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
gastric contrast ultrasound
Description:
Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity
with oral water, contrast agent and ultrasound contrast agent before the examination to
remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous
echo area and form a good acoustic sound. Interface contrast, more clearly showing the
gastric wall hierarchy and the ultrasound examination method of the lesions.
In this way, not only the changes of the gastrointestinal mucosa can be found, but also
the submucosal tumors of the gastrointestinal tract can be clearly displayed, the
internal structural characteristics of the tumor, the extent of the lesions, the depth of
infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can
be displayed.
Arm group label:
Experimental group
Summary:
In this study, the clinical data of patients diagnosed with gastric cancer who were ready
for surgery were examined by contrast-enhanced ultrasonography and gastric-enhanced CT
before surgery. Based on the results of postoperative pathological examinations, the
diagnostic accuracy of gastric filling contrast-enhanced ultrasonography and gastric
contrast-enhanced CT in different stages of gastric cancer was compared and analyzed.
Provide better guidance for follow-up clinical practice.
Criteria for eligibility:
Study pop:
Patients with gastric cancer who are ready for surgery
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Age: 18~80 years old, male or female;
2. Diagnosed with gastric cancer by histology or cytology;
3. No distant multiple metastasis;
4. ECOG score 0-2;
5. Heart, lung, liver and kidney function can tolerate surgery;
6. Patients and their families can understand and be willing to participate in this
clinical study, and sign the informed consent.
Exclusion Criteria:
1. Previous history of malignant tumor or recent diagnosis combined with other
malignant tumors;
2. Patients with gastrointestinal perforation, gastrointestinal bleeding, etc.
requiring emergency surgery;
3. Patients with previous gastroduodenal surgery;
4. Preoperative neoadjuvant therapy;
5. Patients and their families refuse surgical treatment;
6. ASA grade ≥ IV and/or ECOG performance status score > 2;
7. Patients with severe liver and kidney function, cardiopulmonary function,
coagulation dysfunction or combined with serious underlying diseases who cannot
tolerate surgery;
8. Have a history of serious mental illness;
9. Pregnant or lactating women;
10. Patients with other clinical and laboratory conditions considered by the researchers
should not participate in this trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Start date:
December 1, 2022
Completion date:
December 30, 2024
Lead sponsor:
Agency:
The First Hospital of Jilin University
Agency class:
Other
Source:
The First Hospital of Jilin University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05596864
